Columbia, Mo. -- In a study that could have applications in human medicine as well, researchers at the University of Missouri are studying potential biomarkers in dogs that could lead to early diagnosis of osteoarthritis, helping identify patients at higher risk for the disease.
Columbia, Mo.
-- In a study that could have applications in human medicine as well, researchers at the University of Missouri are studying potential biomarkers in dogs that could lead to early diagnosis of osteoarthritis (OA), helping identify patients at higher risk for the disease.
Because OA is most often diagnosed in later, irreversible stages, treatment usually is limited to slowing disease progress and decreasing pain. "By developing methods for earlier diagnosis, prevention or even curative treatment strategies ... become more realistic," says James Cook, professor of veterinary medicine and surgery at MU. "Biomarkers could detect the disease before pain and swelling occurs, and owners could take preventive measures, such as modifying the pet's activities or diet, helping them lose weight and strengthening their joints."
The MU research team examined possible biomarkers in joint-lubricating synovial fluid because it is known to respond to joint injury. Samples taken from dogs showed that synovial fluid quality and quantity were altered in injured stifle joints.
"Our team ... is making progress in developing simple tests on blood, urine and synoval fluid that show great promise for helping us diagnose impending OA before it is too late," Cook says.
Some 20 percent of middle-aged dogs and 90 percent of older dogs have OA in one or more joints, and the disease is equally common in humans and horses.
The MU study, titled "Examination of Synovial Fluid Hyaluronan Quantity and Quality in Stifle Joints of Dogs with Osteoarthritis," was published in the American Journal of Veterinary Research. Co-authors are Cook, Rachel Venable, doctoral student; Aaron Stoker, assistant professor; Cristi Cook, clinical assistant professor; and Mary Cockrell, research specialist.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More